dc.contributor.author |
Okonkwo, Prosper |
|
dc.date.accessioned |
2024-07-11T10:10:18Z |
|
dc.date.available |
2024-07-11T10:10:18Z |
|
dc.date.issued |
2019 |
|
dc.identifier.uri |
http://localhost:8080/xmlui/handle/123456789/2597 |
|
dc.description.abstract |
Objectives and Method: There are growing concerns of tenofovir disoproxil fumarate (TDF)–associated renal toxicity. We
evaluated the effect of long-term TDF exposure on renal function in a cohort of HIV-1-infected Nigerians between 2006 and 2015.
Multivariate logistic regression was used to identify predictors of renal impairment at different time over 144 weeks of antiretroviral
therapy (ART). Results: Data of 4897 patients, median age 42 years (interquartile range: 36-49), and 61% females were analyzed.
The prevalence of renal impairment increased from 10% at week 24 to 45% at 144 weeks in TDF-exposed participants compared
to an increase from 8% at 24 weeks to 14% at 144 weeks in TDF-unexposed participants. Tenofovir disoproxil fumarate exposure
predicted the risk of renal impairment at 144 weeks of ART (odds ratio: 2.36; 95% confidence interval: 1.28-4.34). Conclusion:
Long-term exposure to TDF-based ART significantly increases the likelihood of renal impairment. The continued use of TDFbased
regimen in our setting should be reviewed. We recommend the urgent introduction of tenofovir alafenamide–based
regimen in the HIV treatment guidelines of Nigeria and other resource-limited countries. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Journal of the International Association of Providers of AIDS Care |
en_US |
dc.relation.ispartofseries |
VOL.18; |
|
dc.subject |
HIV |
en_US |
dc.subject |
ART |
en_US |
dc.subject |
tenofovir, |
en_US |
dc.title |
Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults |
en_US |
dc.type |
Article |
en_US |